Kura Oncology (NASDAQ:KURA) Upgraded to "Hold" by StockNews.com

Kura Oncology (NASDAQ:KURA - Get Free Report) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Wednesday.

Several other brokerages have also issued reports on KURA. Mizuho began coverage on Kura Oncology in a report on Friday, December 22nd. They set a "buy" rating and a $26.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $32.00 target price on shares of Kura Oncology in a report on Wednesday, March 6th. JMP Securities raised their target price on Kura Oncology from $22.00 to $32.00 and gave the company a "market outperform" rating in a report on Wednesday, January 31st. Finally, Wedbush restated an "outperform" rating and set a $37.00 target price on shares of Kura Oncology in a report on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology has an average rating of "Moderate Buy" and an average target price of $28.28.

Kura Oncology Stock Down 0.9 %

Shares of NASDAQ:KURA traded down $0.18 during midday trading on Wednesday, hitting $20.34. 553,568 shares of the stock were exchanged, compared to its average volume of 1,444,057. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.26 and a current ratio of 12.26. Kura Oncology has a 52-week low of $7.41 and a 52-week high of $24.17. The business's fifty day simple moving average is $20.94 and its two-hundred day simple moving average is $14.35. The company has a market capitalization of $1.55 billion, a PE ratio of -9.78 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.01. During the same period in the previous year, the business earned ($0.49) EPS. As a group, research analysts predict that Kura Oncology will post -2.35 earnings per share for the current fiscal year.

Insider Transactions at Kura Oncology

In other news, SVP Thomas James Doyle sold 2,318 shares of Kura Oncology stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $41,260.40. Following the transaction, the senior vice president now directly owns 48,093 shares in the company, valued at $856,055.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Kura Oncology news, COO Kathleen Ford sold 1,496 shares of Kura Oncology stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the sale, the chief operating officer now directly owns 21,602 shares of the company's stock, valued at $384,515.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 2,318 shares of Kura Oncology stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the sale, the senior vice president now directly owns 48,093 shares in the company, valued at $856,055.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 96,919 shares of company stock worth $1,946,415. Company insiders own 5.60% of the company's stock.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in KURA. US Bancorp DE raised its stake in shares of Kura Oncology by 45.0% in the fourth quarter. US Bancorp DE now owns 2,097 shares of the company's stock valued at $30,000 after acquiring an additional 651 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Kura Oncology by 46.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,710 shares of the company's stock worth $50,000 after purchasing an additional 1,501 shares during the last quarter. Signaturefd LLC raised its position in Kura Oncology by 40.4% in the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company's stock worth $72,000 after purchasing an additional 1,449 shares during the last quarter. Royal Bank of Canada raised its position in Kura Oncology by 81.5% in the 2nd quarter. Royal Bank of Canada now owns 6,801 shares of the company's stock worth $72,000 after purchasing an additional 3,053 shares during the last quarter. Finally, Pale Fire Capital SE bought a new position in Kura Oncology in the 3rd quarter worth approximately $92,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.